Answers are grounded in this paper and cite their sources.
Questions statin benefit for dementia prevention in older adults; challenges prior observational associations but leaves open need for randomized trials.
BACKGROUND AND OBJECTIVES: Several observational studies have reported a lower risk of dementia in statin users compared with nonusers, but these findings may be susceptible to bias. Whether statins prevent dementia would ideally be studied in a large, randomized trial that includes older adults followed for a long follow-up period. In the absence of such a trial, we can explicitly emulate a target trial of statins and risk of dementia using observational data. METHODS: Using electronic health records from the US Department of Veterans Affairs, we emulated a target trial of statin therapy and 10-year risk of dementia. Eligible individuals were men aged 60 years or older with no history of dementia, cardiovascular disease, chronic renal disease, diabetes, or statin use in the past year. The treatment strategies to be compared were initiation of any statin and continuation over follow-up (until the development of a contraindication or serious health condition) vs no statin initiation. The outcome of interest was diagnosis of any dementia. Risks were estimated through a pooled logistic regression model adjusted for baseline and time-varying covariates. RESULTS: A total of 81,599 statin initiators and 843,615 noninitiators were eligible for this study. The median age (interquartile range) was 64.3 years (61.2-70.3), and 11.7% were Black. The estimated 10-year dementia risks were 9.4% (95% CI 8.5-9.9) for statins and 9.6% (95% CI 8.9-10.3) for no statins. The corresponding risk difference was -0.2% (95% CI -0.9 to 0.4), and the risk ratio was 0.98 (95% CI 0.89-1.15). Estimates were similar within subgroups defined at baseline according to age, race, and frailty status based on deficit accumulation. CONCLUSION: Although the possibility of unmeasured confounding or misclassification cannot be entirely excluded, as in any observational study, this study involving a nationwide cohort of older male US veterans without prior cardiovascular disease suggests that statin therapy does not meaningfully influence dementia incidence over 10 years. CLASSIFICATION OF EVIDENCE: Per American Academy of Neurology Class of Evidence Classification, this study provides Class III evidence that statins do not reduce the incidence of dementia in men aged 60 years or older.
No takes yet. Share an insight, caveat, or question.
Szmulewicz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: